Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
Public ClinicalTrials.gov record NCT02322021. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2 study to evaluate safety and efficacy in participants with Mild Cognitive Impairment due to Alzheimer's Disease/Prodromal Alzheimer's Disease (referred to as MCI/Prodromal) and mild to moderate dementia due to Alzheimer's Disease (referred to as mild to moderate AD). This study will have a Core Phase and an Extension Phase.
Study identification
- NCT ID
- NCT02322021
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 70 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 26, 2014 (Actual)
- Primary completion
- Dec 20, 2019 (Actual)
- Completion
- Dec 20, 2019 (Actual)
- Last update posted
- Mar 5, 2021
2014 – 2019
United States locations
- U.S. sites
- 21
- U.S. states
- 10
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Bellflower | California | — | — |
| Not listed | Costa Mesa | California | — | — |
| Not listed | Glendale | California | — | — |
| Not listed | Irvine | California | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | Boca Raton | Florida | — | — |
| Not listed | Brooksville | Florida | — | — |
| Not listed | Lake Worth | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Port Charlotte | Florida | — | — |
| Not listed | Atlanta | Georgia | — | — |
| Not listed | Savannah | Georgia | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Kalamazoo | Michigan | — | — |
| Not listed | Mount Arlington | New Jersey | — | — |
| Not listed | Scotch Plains | New Jersey | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Port Royal | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02322021, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02322021 live on ClinicalTrials.gov.